List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8830515/publications.pdf Version: 2024-02-01

		30068	33889
187	11,366	54	99
papers	citations	h-index	g-index
014	014	014	16457
214	214	214	16457
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A promoter-level mammalian expression atlas. Nature, 2014, 507, 462-470.	27.8	1,838
2	Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science, 2015, 347, 1010-1014.	12.6	517
3	Coronary in-stent restenosis: Current status and future strategies. Journal of the American College of Cardiology, 2002, 39, 183-193.	2.8	346
4	Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nature Medicine, 2003, 9, 1026-1032.	30.7	337
5	Sp1 Phosphorylation and Its Regulation of Gene Transcription. Molecular and Cellular Biology, 2009, 29, 2483-2488.	2.3	287
6	Interplay of Sp1 and Egr-1 in the Proximal Platelet-derived Growth Factor A-Chain Promoter in Cultured Vascular Endothelial Cells. Journal of Biological Chemistry, 1995, 270, 27679-27686.	3.4	260
7	Early Growth Response-1 in Cardiovascular Pathobiology. Circulation Research, 2006, 98, 186-191.	4.5	252
8	New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nature Medicine, 1999, 5, 1264-1269.	30.7	232
9	FANTOM5 CAGE profiles of human and mouse samples. Scientific Data, 2017, 4, 170112.	5.3	195
10	Egr-1 is Activated in Endothelial Cells Exposed to Fluid Shear Stress and Interacts With a Novel Shear-Stress-Response Element in the PDGF A-Chain Promoter. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2280-2286.	2.4	190
11	Dominantly Inherited Constitutional Epigenetic Silencing of MLH1 in a Cancer-Affected Family Is Linked to a Single Nucleotide Variant within the 5′UTR. Cancer Cell, 2011, 20, 200-213.	16.8	158
12	Galectin-1 Interacts with the $\hat{1}\pm5\hat{1}^21$ Fibronectin Receptor to Restrict Carcinoma Cell Growth via Induction of p21 and p27. Journal of Biological Chemistry, 2005, 280, 37266-37277.	3.4	148
13	Collagen antibody-induced arthritis. Nature Protocols, 2006, 1, 2512-2516.	12.0	148
14	Effect of Deoxyribozymes Targeting c-Jun on Solid Tumor Growth and Angiogenesis in Rodents. Journal of the National Cancer Institute, 2004, 96, 683-696.	6.3	147
15	Inducible Expression of Egr-1–Dependent Genes. Circulation Research, 1997, 81, 457-461.	4.5	138
16	DNAzyme technology and cancer therapy: cleave and let die. Molecular Cancer Therapeutics, 2008, 7, 243-251.	4.1	130
17	Isolation and Characterization of a Novel Zinc-finger Protein with Transcriptional Repressor Activity. Journal of Biological Chemistry, 1995, 270, 22143-22152.	3.4	123
18	The Yin and Yang of <scp>YY</scp> 1 in tumor growth and suppression. International Journal of Cancer. 2018, 143, 460-465.	5.1	121

#	Article	IF	CITATIONS
19	Protein-Protein Interaction between Fli-1 and GATA-1 Mediates Synergistic Expression of Megakaryocyte-Specific Genes through Cooperative DNA Binding. Molecular and Cellular Biology, 2003, 23, 3427-3441.	2.3	114
20	Brothers in Arms. American Journal of Pathology, 2007, 171, 1079-1088.	3.8	113
21	Hemodynamics, Endothelial Gene Expression, and Atherogenesis. Annals of the New York Academy of Sciences, 1997, 811, 1-11.	3.8	112
22	Sp1 Is a Component of the Cytokine-inducible Enhancer in the Promoter of Vascular Cell Adhesion Molecule-1. Journal of Biological Chemistry, 1995, 270, 28903-28909.	3.4	110
23	Early Growth Response Factor-1 Induction by Injury Is Triggered by Release and Paracrine Activation by Fibroblast Growth Factor-2. American Journal of Pathology, 1999, 154, 937-944.	3.8	109
24	Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Research, 2004, 32, 3065-3069.	14.5	108
25	Catalytic Oligodeoxynucleotides Define a Key Regulatory Role for Early Growth Response Factor-1 in the Porcine Model of Coronary In-Stent Restenosis. Circulation Research, 2001, 89, 670-677.	4.5	105
26	Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nature Biotechnology, 2006, 24, 856-863.	17.5	104
27	c-Jun Regulates Vascular Smooth Muscle Cell Growth and Neointima Formation after Arterial Injury. Journal of Biological Chemistry, 2002, 277, 22985-22991.	3.4	97
28	Endothelial Gene Regulation by Laminar Shear Stress. Advances in Experimental Medicine and Biology, 1997, 430, 155-164.	1.6	97
29	Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma. Journal of the National Cancer Institute, 2003, 95, 1394-1403.	6.3	96
30	ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. Journal of Cellular Biochemistry, 2003, 89, 289-300.	2.6	95
31	Induction of Platelet-derived Growth Factor B-chain Expression by Transforming Growth Factor-β Involves Transactivation by Smads. Journal of Biological Chemistry, 2000, 275, 16709-16716.	3.4	91
32	Macrophage Migration Inhibitory Factor Increases Leukocyte–Endothelial Interactions in Human Endothelial Cells via Promotion of Expression of Adhesion Molecules. Journal of Immunology, 2010, 185, 1238-1247.	0.8	89
33	Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). Lancet, The, 2013, 381, 1835-1843.	13.7	87
34	The role of platelet α-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. Blood, 2000, 95, 3094-3101.	1.4	85
35	TRAIL Stimulates Proliferation of Vascular Smooth Muscle Cells via Activation of NF-κB and Induction of Insulin-like Growth Factor-1 Receptor. Journal of Biological Chemistry, 2008, 283, 7754-7762.	3.4	83
36	Current and Potential Treatments for Cervical Cancer. Current Cancer Drug Targets, 2013, 13, 205-220.	1.6	83

#	Article	IF	CITATIONS
37	Early Growth Response-1 Regulates Angiopoietin-1-Induced Endothelial Cell Proliferation, Migration, and Differentiation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 209-216.	2.4	77
38	Sp1 Inhibits Proliferation and Induces Apoptosis in Vascular Smooth Muscle Cells by Repressing p21WAF1/Cip1 Transcription and Cyclin D1-Cdk4-p21WAF1/Cip1 Complex Formation. Journal of Biological Chemistry, 2003, 278, 32537-32543.	3.4	72
39	Fibroblast Growth Factor-2 Represses Platelet-derived Growth Factor Receptor-α (PDGFR-α) Transcription via ERK1/2-dependent Sp1 Phosphorylation and an Atypical cis-Acting Element in the Proximal PDGFR-α Promoter. Journal of Biological Chemistry, 2004, 279, 2377-2382.	3.4	72
40	Early Growth Response Gene 1 (EGR1) Regulates Heparanase Gene Transcription in Tumor Cells. Journal of Biological Chemistry, 2005, 280, 35136-35147.	3.4	72
41	TRAIL Promotes VSMC Proliferation and Neointima Formation in a FGF-2–, Sp1 Phosphorylation–, and NFκB-Dependent Manner. Circulation Research, 2010, 106, 1061-1071.	4.5	72
42	Sp1 Phosphorylation Regulates Apoptosis via Extracellular FasL-Fas Engagement. Journal of Biological Chemistry, 2001, 276, 4964-4971.	3.4	71
43	Regulation of Inducible Heparanase Gene Transcription in Activated T Cells by Early Growth Response 1. Journal of Biological Chemistry, 2003, 278, 50377-50385.	3.4	71
44	Yin Yang-1 Inhibits Vascular Smooth Muscle Cell Growth and Intimal Thickening by Repressing p21 WAF1/Cip1 Transcription and p21 WAF1/Cip1 -Cdk4-Cyclin D1 Assembly. Circulation Research, 2007, 101, 146-155.	4.5	67
45	Phosphomannopentaose Sulfate (Plâ€88): Heparan Sulfate Mimetic with Clinical Potential in Multiple Vascular Pathologies. Cardiovascular Drug Reviews, 2004, 22, 1-6.	4.1	63
46	Ets-1 Positively Regulates Fas Ligand Transcription via Cooperative Interactions with Sp1. Journal of Biological Chemistry, 2002, 277, 36244-36252.	3.4	61
47	Vascular Smooth Muscle Cell Proliferation and Regrowth after Mechanical Injury in Vitro Are. Egr-1/NGFI-A-Dependent. American Journal of Pathology, 1999, 155, 897-905.	3.8	60
48	DNAzyme Targeting c- <i>jun</i> Suppresses Skin Cancer Growth. Science Translational Medicine, 2012, 4, 139ra82.	12.4	60
49	Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin–restricted miRNA antagonists of miR-27. Blood, 2013, 122, 2911-2919.	1.4	60
50	Sp1 phosphorylation regulates inducible expression of platelet-derived growth factor B-chain gene via atypical protein kinase C-zeta. Nucleic Acids Research, 2001, 29, 1027-1033.	14.5	58
51	GILZ Overexpression Inhibits Endothelial Cell Adhesive Function through Regulation of NF-κB and MAPK Activity. Journal of Immunology, 2013, 191, 424-433.	0.8	57
52	Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. Journal of Clinical Investigation, 2000, 106, 1189-1195.	8.2	57
53	Crucial Role for Early Growth Response-1 in the Transcriptional Regulation of miR-20b in Breast Cancer. Oncotarget, 2013, 4, 1373-1387.	1.8	57
54	Regulation of PDGF-B in Endothelial Cells Exposed to Cyclic Strain. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 349-355.	2.4	56

#	Article	IF	CITATIONS
55	GC Factor 2 Represses Platelet-Derived Growth Factor A-Chain Gene Transcription and Is Itself Induced by Arterial Injury. Circulation Research, 1999, 84, 1258-1267.	4.5	56
56	Modulation of Growth Factor Gene Expression in Vascular Cells by Oxidative Stress. Endothelium: Journal of Endothelial Cell Research, 2004, 11, 133-139.	1.7	56
57	Blockade of Vascular Smooth Muscle Cell Proliferation and Intimal Thickening After Balloon Injury by the Sulfated Oligosaccharide PI-88. Circulation Research, 2003, 92, e70-7.	4.5	54
58	Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochemical and Biophysical Research Communications, 2010, 397, 729-734.	2.1	54
59	PDGF β-Receptor Kinase Activity and ERK1/2 Mediate Glycosaminoglycan Elongation on Biglycan and Increases Binding to LDL. Endocrinology, 2010, 151, 4356-4367.	2.8	52
60	Angiotensin II (ATII)-inducible Platelet-derived Growth Factor A-chain Gene Expression Is p42/44 Extracellular Signal-regulated Kinase-1/2 and Egr-1-dependent and Mediated via the ATII Type 1 but Not Type 2 Receptor. Journal of Biological Chemistry, 1999, 274, 23726-23733.	3.4	51
61	Rat models of myocardial infarction. Thrombosis and Haemostasis, 2006, 96, 602-610.	3.4	51
62	Activation Transcription Factor-4 Induced by Fibroblast Growth Factor-2 Regulates Vascular Endothelial Growth Factor-A Transcription in Vascular Smooth Muscle Cells and Mediates Intimal Thickening in Rat Arteries Following Balloon Injury. Circulation Research, 2008, 103, 378-387.	4.5	51
63	Zinc Finger Transcription Factors Mediate High Constitutive Platelet-derived Growth Factor-B Expression in Smooth Muscle Cells Derived from Aortae of Newborn Rats. Journal of Biological Chemistry, 1998, 273, 5758-5764.	3.4	50
64	Oxidative stress regulates IGF1R expression in vascular smooth-muscle cells via p53 and HDAC recruitment. Biochemical Journal, 2007, 407, 79-87.	3.7	50
65	Induction of the Transcriptional Repressor Yin Yang-1 by Vascular Cell Injury. Journal of Biological Chemistry, 2001, 276, 41143-41149.	3.4	49
66	NF1/X represses PDGF A-chain transcription by interacting with Sp1 and antagonizing Sp1 occupancy of the promoter. EMBO Journal, 2002, 21, 334-343.	7.8	49
67	Ets-1 Stimulates Platelet-Derived Growth Factor A-Chain Gene Transcription and Vascular Smooth Muscle Cell Growth via Cooperative Interactions With Sp1. Circulation Research, 2004, 95, 479-487.	4.5	48
68	Neutralizing the pathological effects of extracellular histones with small polyanions. Nature Communications, 2020, 11, 6408.	12.8	48
69	Vascular Smooth Muscle Cells Express the Transcriptional Corepressor NAB2 in Response to Injury. American Journal of Pathology, 1999, 155, 1311-1317.	3.8	47
70	FGF-1–Induced Platelet-Derived Growth Factor-A Chain Gene Expression in Endothelial Cells Involves Transcriptional Activation by Early Growth Response Factor-1. Circulation Research, 1997, 81, 282-288.	4.5	47
71	Catalytic Antisense DNA Molecules Targeting Egr-1 Inhibit Neointima Formation following Permanent Ligation of Rat Common Carotid Arteries. Thrombosis and Haemostasis, 2002, 87, 134-140.	3.4	46
72	Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth. Nucleic Acids Research, 2004, 32, 2281-2285.	14.5	46

#	Article	IF	CITATIONS
73	Ets-1 Protects Vascular Smooth Muscle Cells from Undergoing Apoptosis by Activating p21WAF1/Cip1. Journal of Biological Chemistry, 2003, 278, 27903-27909.	3.4	45
74	Regulatory roles of c-jun in H5N1 influenza virus replication and host inflammation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2479-2488.	3.8	45
75	Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. Journal of Molecular Medicine, 2001, 79, 695-706.	3.9	44
76	Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. Journal of Cellular Biochemistry, 2001, 81, 523-534.	2.6	44
77	Fibroblast Growth Factor-2 Induction of Platelet-derived Growth Factor-C Chain Transcription in Vascular Smooth Muscle Cells Is ERK-dependent but Not JNK-dependent and Mediated by Egr-1. Journal of Biological Chemistry, 2004, 279, 40289-40295.	3.4	44
78	The Cytoplasmic Domain of Tissue Factor Contributes to Leukocyte Recruitment and Death in Endotoxemia. American Journal of Pathology, 2004, 165, 331-340.	3.8	44
79	A Key Role for Early Growth Response-1 and Nuclear Factor-κB in Mediating and Maintaining GRO/CXCR2 Proliferative Signaling in Esophageal Cancer. Molecular Cancer Research, 2009, 7, 755-764.	3.4	44
80	Phosphorylation and Acetylation of Histone H3 and Autoregulation by Early Growth Response 1 Mediate Interleukin 11² Induction of Early Growth Response 1 Transcription. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 536-545.	2.4	42
81	Sp1, acetylated histoneâ€3 and p300 regulate TRAIL transcription: Mechanisms of PDGFâ€BBâ€mediated VSMC proliferation and migration. Journal of Cellular Biochemistry, 2012, 113, 2597-2606.	2.6	40
82	Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget, 2018, 9, 21613-21627.	1.8	39
83	c-Jun DNAzymes Inhibit Myocardial Inflammation, ROS Generation, Infarct Size, and Improve Cardiac Function After Ischemia-Reperfusion Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1836-1842.	2.4	37
84	Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway. Haematologica, 2010, 95, 1745-1753.	3.5	37
85	Deoxyribozymes as Catalytic Nanotherapeutic Agents. Cancer Research, 2019, 79, 879-888.	0.9	37
86	Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection. Oncotarget, 2019, 10, 216-244.	1.8	37
87	Interplay Between Heme Oxygenase-1 and the Multifunctional Transcription Factor Yin Yang 1 in the Inhibition of Intimal Hyperplasia. Circulation Research, 2010, 107, 1490-1497.	4.5	35
88	c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Molecular Cancer Therapeutics, 2008, 7, 1909-1912.	4.1	34
89	Inducible platelet-derived growth factor D-chain expression by angiotensin II and hydrogen peroxide involves transcriptional regulation by Ets-1 and Sp1. Blood, 2006, 107, 2322-2329.	1.4	31
90	c- <i>Jun</i> Is Critical for the Progression of Osteosarcoma: Proof in an Orthotopic Spontaneously Metastasizing Model. Molecular Cancer Research, 2008, 6, 1289-1292.	3.4	31

#	Article	IF	CITATIONS
91	Angiotensin II–Inducible Smooth Muscle Cell Apoptosis Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and FasL-Fas Engagement. Circulation Research, 2009, 105, 422-430.	4.5	31
92	Early Growth Responseâ€1, an Integrative Sensor in Cardiovascular and Inflammatory Disease. Journal of the American Heart Association, 2021, 10, e023539.	3.7	31
93	Suppression of growth factor expression and human vascular smooth muscle cell growth by small interfering RNA targeting EGR-1. Journal of Cellular Biochemistry, 2007, 100, 1526-1535.	2.6	30
94	Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. Journal of Microencapsulation, 2008, 25, 421-425.	2.8	30
95	Angiotensin II–Inducible Platelet-Derived Growth Factor-D Transcription Requires Specific Ser/Thr Residues in the Second Zinc Finger Region of Sp1. Circulation Research, 2008, 102, e38-51.	4.5	29
96	Comparative transcriptomics of primary cells in vertebrates. Genome Research, 2020, 30, 951-961.	5.5	29
97	Antisense Egr-1 RNA driven by the CMV promoter is an inhibitor of vascular smooth muscle cell proliferation and regrowth after injury. Journal of Cellular Biochemistry, 2002, 84, 575-582.	2.6	28
98	Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biology and Therapy, 2008, 7, 1033-1036.	3.4	28
99	Intracoronary delivery of DNAzymes targeting human EGRâ€l reduces infarct size following myocardial ischaemia reperfusion. Journal of Pathology, 2012, 227, 157-164.	4.5	28
100	Early growth response-1 in the pathogenesis of cardiovascular disease. Journal of Molecular Medicine, 2016, 94, 747-753.	3.9	28
101	The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. Cancer Letters, 2019, 459, 268-276.	7.2	28
102	Drug-induced Immune Thrombocytopenia. Hematology/Oncology Clinics of North America, 2013, 27, 521-540.	2.2	27
103	Remote Ischemic Preconditioning Induces Cardioprotective Autophagy and Signals through the IL-6-Dependent JAK-STAT Pathway. International Journal of Molecular Sciences, 2020, 21, 1692.	4.1	27
104	Early Growth Response-1: Blocking Angiogenesis by Shooting the Messenger. Cell Cycle, 2004, 3, 9-10.	2.6	26
105	Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biology and Therapy, 2008, 7, 1297-1301.	3.4	26
106	Selective Inhibition of the Master Regulator Transcription Factor Egrâ€1 With Catalytic Oligonucleotides Reduces Myocardial Injury and Improves Left Ventricular Systolic Function in a Preclinical Model of Myocardial Infarction. Journal of the American Heart Association, 2013, 2, e000023.	3.7	26
107	Nuclear import of early growth response-1 involves importin-7 and the novel nuclear localization signal serine-proline-serine. International Journal of Biochemistry and Cell Biology, 2011, 43, 905-912.	2.8	25
108	Emerging therapeutic approaches in the management of retinal angiogenesis and edema. Journal of Molecular Medicine, 2011, 89, 343-361.	3.9	25

#	Article	IF	CITATIONS
109	Peroxide-Inducible Ets-1 Mediates Platelet-Derived Growth Factor Receptor-α Gene Transcription in Vascular Smooth Muscle Cells. American Journal of Pathology, 2005, 167, 1149-1159.	3.8	24
110	JUN siRNA regulates matrix metalloproteinase-2 expression, microvascular endothelial growth and retinal neovascularisation. Journal of Cell Science, 2006, 119, 3219-3226.	2.0	24
111	c-Jun Regulates Shear- and Injury-inducible Egr-1 Expression, Vein Graft Stenosis after Autologous End-to-Side Transplantation in Rabbits, and Intimal Hyperplasia in Human Saphenous Veins. Journal of Biological Chemistry, 2010, 285, 4038-4048.	3.4	23
112	Recruitment and maturation of the coronary collateral circulation: Current understanding and perspectives in arteriogenesis. Microvascular Research, 2020, 132, 104058.	2.5	23
113	Transcriptional Dynamics Reveal Critical Roles for Non-coding RNAs in the Immediate-Early Response. PLoS Computational Biology, 2015, 11, e1004217.	3.2	22
114	Angiotensin II induction of PDGF-C expression is mediated by AT1 receptor-dependent Egr-1 transactivation. Nucleic Acids Research, 2008, 36, 1941-1951.	14.5	20
115	"Summer Shiftâ€: A Potential Effect of Sunshine on the Time Onset of STâ€Elevation Acute Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	20
116	IL-1beta Signals through the EGF Receptor and Activates Egr-1 through MMP-ADAM. PLoS ONE, 2012, 7, e39811.	2.5	20
117	Platelet-derived growth factor and alternative splicing: A review. Pathology, 1992, 24, 280-290.	0.6	20
118	DNAzymes: cutting a path to a new class of therapeutics. Current Opinion in Molecular Therapeutics, 2002, 4, 119-21.	2.8	19
119	von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter. Journal of Cellular Biochemistry, 2002, 85, 490-495.	2.6	18
120	Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG. Blood, 2010, 116, 1958-1960.	1.4	18
121	Extracellular matrix is a source of mitogenically active platelet-derived growth factor. , 1996, 168, 322-332.		17
122	PDGF-D Expression Is Down-Regulated by TGFÎ ² in Fibroblasts. PLoS ONE, 2014, 9, e108656.	2.5	17
123	Activation transcription factor-4 and the acute vascular response to injury. Journal of Molecular Medicine, 2010, 88, 545-552.	3.9	16
124	MicroRNA miR-191 targets the zinc finger transcription factor Egr-1 and suppresses intimal thickening after carotid injury. International Journal of Cardiology, 2016, 212, 299-302.	1.7	16
125	Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB–VCAM-1 axis. Science Advances, 2020, 6, eaaz7815.	10.3	16
126	Vascular smooth muscle cell-specific regulation of cyclin-dependent kinase inhibitor p21WAF1/Cip1 transcription by Sp1 is mediated via distinctcis-acting positive and negative regulatory elements in the proximal p21WAF1/Cip1 promoter. Journal of Cellular Biochemistry, 2004, 93, 904-916.	2.6	15

#	Article	IF	CITATIONS
127	Platelet-Derived Growth Factor-BB Mediates Cell Migration through Induction of Activating Transcription Factor 4 and Tenascin-C. American Journal of Pathology, 2012, 180, 2590-2597.	3.8	15
128	Melanoma protective antitumor immunity activated by catalytic DNA. Oncogene, 2018, 37, 5115-5126.	5.9	15
129	Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries. Thrombosis and Haemostasis, 2002, 87, 134-40.	3.4	15
130	Structural basis for the extracellular retention of PDGF A-chain using a synthetic peptide corresponding to exon 6. Peptides, 1994, 15, 133-137.	2.4	14
131	Recent developments in drug-eluting stents. Journal of Molecular Medicine, 2011, 89, 545-553.	3.9	14
132	Transcription Factors Targeted by miRNAs Regulating Smooth Muscle Cell Growth and Intimal Thickening after Vascular Injury. International Journal of Molecular Sciences, 2019, 20, 5445.	4.1	14
133	Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGFβ receptor phosphorylation. Archives of Biochemistry and Biophysics, 2012, 525, 25-31.	3.0	13
134	Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). International Journal of Cardiology, 2013, 168, 3659-3664.	1.7	13
135	DNAzyme Delivery Approaches in Biological Settings. Current Medicinal Chemistry, 2013, 20, 3448-3455.	2.4	13
136	Acute Local Release of Fibroblast Growth Factor-2 but not Transforming Growth Factor-β1 following Coronary Stenting. Thrombosis and Haemostasis, 2001, 85, 574-576.	3.4	12
137	The role of c-jun in PDTC-sensitive flow-dependent restenosis after angioplasty and stenting. Atherosclerosis, 2007, 194, 364-371.	0.8	11
138	Repression of PDGF-R-α after cellular injury involves TNF-α, formation of a c-Fos-YY1 complex, and negative regulation by HDAC. American Journal of Physiology - Cell Physiology, 2012, 302, C1590-C1598.	4.6	11
139	Yin Yang-1 inhibits tumor cell growth and inhibits p21WAF1/Cip1 complex formation with cdk4 and cyclin D1. International Journal of Oncology, 2012, 40, 1575-80.	3.3	11
140	Discovery of widespread transcription initiation at microsatellites predictable by sequence-based deep neural network. Nature Communications, 2021, 12, 3297.	12.8	11
141	SUMOylation Regulates the Transcriptional Repression Activity of FOG-2 and Its Association with GATA-4. PLoS ONE, 2012, 7, e50637.	2.5	10
142	Promoter Usage and Dynamics in Vascular Smooth Muscle Cells Exposed to Fibroblast Growth Factor-2 or Interleukin-1l². Scientific Reports, 2018, 8, 13164.	3.3	10
143	Pharmaceutical patents: reconciling the human right to health with the incentive to invent. Drug Discovery Today, 2020, 25, 1135-1141.	6.4	10
144	Mechanisms of angiotensin II-induced platelet-derived growth factor gene expression. Molecular and Cellular Biochemistry, 2000, 212, 183-186.	3.1	9

9

#	Article	IF	CITATIONS
145	Histone Deacetylase-1 Is Enriched at the Platelet-derived Growth Factor-D Promoter in Response to Interleukin-1β and Forms a Cytokine-inducible Gene-silencing Complex with NF-κB p65 and Interferon Regulatory Factor-1. Journal of Biological Chemistry, 2009, 284, 35101-4263.	3.4	9
146	Injury-induced Platelet-derived Growth Factor Receptor-α Expression Mediated by Interleukin-1β (IL-1β) Release and Cooperative Transactivation by NF-κB and ATF-4. Journal of Biological Chemistry, 2009, 284, 27933-27943.	3.4	9
147	Reduced Retinal Microvascular Density, Improved Forepaw Reach, Comparative Microarray and Gene Set Enrichment Analysis with c-jun Targeting DNA Enzyme. PLoS ONE, 2012, 7, e39160.	2.5	9
148	Succinobucol induces apoptosis in vascular smooth muscle cells. Free Radical Biology and Medicine, 2012, 52, 871-879.	2.9	9
149	Serine 26 in Early Growth Response†Is Critical for Endothelial Proliferation, Migration, and Network Formation. Journal of the American Heart Association, 2021, 10, e020521.	3.7	9
150	Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent. Cancer Letters, 2021, 522, 57-62.	7.2	9
151	Antisense Egr-1 RNA driven by the CMV promoter is an inhibitor of vascular smooth muscle cell proliferation and regrowth after injury. Journal of Cellular Biochemistry, 2002, 84, 575-82.	2.6	9
152	Early growth response-1: blocking angiogenesis by shooting the messenger. Cell Cycle, 2004, 3, 10-1.	2.6	9
153	A crossreactive antipeptide monoclonal antibody with specificity for lysyl-lysine. Journal of Immunological Methods, 1991, 140, 249-258.	1.4	8
154	Inhibition of intimal thickening after vascular injury with a cocktail of vascular endothelial growth factor and cyclic Arg-Gly-Asp peptide. International Journal of Cardiology, 2016, 220, 185-191.	1.7	8
155	Extracellular signal-regulated kinase-1 phosphorylates early growth response-1 at serine 26. Biochemical and Biophysical Research Communications, 2019, 510, 345-351.	2.1	8
156	Fibroblast growth factor 2 and the transcription factor Egr-1 localise to endothelial cell microvascular channels in human coronary artery occlusion. Thrombosis and Haemostasis, 2005, 93, 172-174.	3.4	7
157	Truncated YY1 interacts with BASP1 through a 339KLK341 motif in YY1 and suppresses vascular smooth muscle cell growth and intimal hyperplasia after vascular injury. Cardiovascular Research, 2021, 117, 2395-2406.	3.8	7
158	Developing Neolignans as Proangiogenic Agents: Stereoselective Total Syntheses and Preliminary Biological Evaluations of the Four Guaiacylglycerol 8- <i>O</i> -4′-Coniferyl Ethers. ACS Omega, 2017, 2, 7375-7388.	3.5	5
159	Repurposing Drugs for Skin Cancer. Current Medicinal Chemistry, 2020, 27, 7214-7221.	2.4	5
160	Left main coronary artery stenosis after percutaneous transluminal coronary angioplasty: Importance of remaining ?minimally invasive?. Catheterization and Cardiovascular Interventions, 1999, 46, 254-255.	1.7	4
161	Novel Negative Regulatory Element in the Platelet-derived Growth Factor B Chain Promoter That Mediates ERK-dependent Transcriptional Repression. Journal of Biological Chemistry, 2000, 275, 11478-11483.	3.4	4
162	Catalytic Oligonucleotides Targeting EGRâ€1 As Potential Inhibitors of Inâ€Stent Restenosis. Annals of the New York Academy of Sciences, 2001, 947, 412-415.	3.8	4

#	Article	IF	CITATIONS
163	The streptozotocin-treated Sprague-Dawley rat: a useful model for the assessment of acute and chronic effects of myocardial ischaemia reperfusion injury in experimental diabetes. Diabetes and Vascular Disease Research, 2007, 4, 153-154.	2.0	4
164	Divergent roles of NF-κB and Egr-1 in flow-dependent restenosis after angioplasty and stenting. Atherosclerosis, 2011, 214, 65-72.	0.8	4
165	Coating Stents With Antirestenotic Drugs: The Blunderbuss or the Magic Bullet?. Circulation, 2002, 105, .	1.6	3
166	BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation. Journal of Inflammation Research, 2021, Volume 14, 1019-1028.	3.5	3
167	Deoxyribozymes as Inhibitors of Vascular Smooth Muscle Cell Growth. Current Pharmaceutical Biotechnology, 2004, 5, 337-339.	1.6	3
168	Therapeutic Perspectives on Pancreatic Cancer. Current Cancer Drug Targets, 2013, 13, 400-410.	1.6	3
169	Coating stents with antirestenotic drugs: the blunderbuss or the magic bullet?. Circulation, 2002, 105, E29.	1.6	3
170	Low flow promotes instent intimal hyperplasia. Atherosclerosis, 2004, 177, 269-274.	0.8	2
171	Suppressing a sick heart. Nature Medicine, 2005, 11, 828-829.	30.7	2
172	Health and medical research funding: an investment in Australia's future. Medical Journal of Australia, 2006, 185, 348-349.	1.7	2
173	Destroyingc-junMessenger: New Insights into Biological Mechanisms of DNAzyme Function. Oncotarget, 2012, 3, 594-595.	1.8	2
174	RNA sequencing identifies genes reliant upon Ser26 in early growth response-1 in vascular endothelial cells exposed to fibroblast growth factor-2. Vascular Pharmacology, 2022, , 106952.	2.1	2
175	Oxidative Stress and Endothelial Dysfunction. Endothelium: Journal of Endothelial Cell Research, 2004, 11, 77-78.	1.7	1
176	DNAzymes as molecular agents that manipulate Egr-1 gene expression. Biochemical Pharmacology, 2004, 68, 1023-1025.	4.4	1
177	The Yin and Yang of YY1 in tumor growth and suppression. , 0, .		1
178	Mechanisms of angiotensin II-induced platelet-derived growth factor gene expression. , 2000, , 183-186.		1
179	Novel and Emerging Therapies in Cardiology and Haematology. Current Drug Targets Cardiovascular & Haematological Disorders, 2003, 3, 101-123.	2.0	1
180	The Endothelium and Cardiovascular Disease: New Developments, New Challenges. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 365-365.	1.7	0

#	Article	IF	CITATIONS
181	Early Growth Response-1 Coupling in Vascular Endothelium. , 2007, , 818-821.		Ο
182	Immediate-early genes as master switches in disease. Cell Biology International, 2008, 32, S3-S3.	3.0	0
183	Response to Abcouwer and Roybal. Circulation Research, 2008, 103, .	4.5	Ο
184	Correction: Macrophage Migration Inhibitory Factor Increases Leukocyte–Endothelial Interactions in Human Endothelial Cells via Promotion of Expression of Adhesion Molecules. Journal of Immunology, 2010, 185, 4959-4959.	0.8	0
185	c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins Journal of Biological Chemistry, 2013, 288, 31918.	3.4	0
186	Recent advances in vascular biology: Selected highlights from IVBM 2008. Thrombosis and Haemostasis, 2009, 101, 997-998.	3.4	0
187	Insights into Roles of Immediate-Early Genes in Angiogenesis. , 2013, , 145-162.		Ο